Suber S. Huang, M.D., MBA, a panelist for a session about late-breaking research, said the presentation about Syfovre complications among patients treated at the Wolfe Eye Clinic in Iowa is one of the most important of this year's annual meeting. Five patients experienced complications from the new drug for geographic atrophy.
In an interview with Managed Healthcare Executive, Suber S. Huang, M.D., MBA, of the Retina Center of Ohio in Cleveland, said the late-breaking presentation by William J. Johnson, M.D., of Wolfe Eye Clinic in Iowa about complications from Syfovre (pegacetacoplan) was “an extremely important” paper. Huang said that although Syfovre has been “successfully and safely used in thousands of patients,” there have been a number of cases of hemorrhagic occlusive vasculitis among treated patients that have led to moderate to severe visual loss.
In his presentation, Johnson discussed five cases of Syfovre complications among the 96 eyes treated with the new drug by Wolfe Eye Clinic retina specialists. In July 2023 the clinic paused use of the drug, according to Johnson.